TrialBlood2005

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.

Sergio Amadori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.